As expected, Myriad Genetics, along with its co-patentees, appealed the decision by the District Court for the Southern District of New York finding its US patents relating to BRCA1 and BRCA2 human genes to be partially invalid (see Genomics Law Report article here).
Patentology has reported previously (here and here) on corresponding proceedings commenced by Maurice Blackburn lawyers against a related Australian patent, licensed exclusively to Genetic Technologies Ltd.
We presume that Myriad, GT, and the other defendants, will also vigorously contest the Australian court action.
- Topics »
- Ask Patentology